Bruton Tyrosine Kinase (BTK) Inhibitors

Ibrutinib, sold under the brand name Imbruvica among others, is a small molecule drug that binds permanently to a protein, Bruton's tyrosine kinase (BTK), that is important in B cells. It is used to treat B cell cancers like mantle cell lymphoma, chronic lymphocytic leukemia, and Waldenström's macroglobulinemia...Wikipedia

 

Manufacturer's Website: Imbruvica

 

Average retail cost:   $13,500/month

Zanubrutinib, sold under the brand name Brukinsa, is for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. It was approved for medical use in the United States in November 2019. Zanubrutinib is classified as a Bruton's tyrosine kinase (BTK) inhibitor

...Wikipedia

 

 

Manufacturer's Website: Brukinsa

                                                                                                                  Average retail cost:   $13,500/month

Acalabrutinib, sold under the brand name Calquence, is a medication used to treat a type of non-Hodgkin lymphoma known as mantle cell lymphoma. Specifically it is for people who had previously been treated with another therapy. As of 2019, it was unclear whether it improved outcomes...Wikipedia

 

 

Manufacturer's Website: Calquence

 

 Average retail cost:   $14,700/month